RDEB tumor profiles indicated altered hepatocyte growth factor (HGF)/hepatocyte growth factor receptor (HGFR/MET) and insulin-like growth factor II (IGF2)/insulin-like growth factor I receptor (IGF1R) dynamics, whereas HN-SCC appeared to take advantage of mitogenic fibroblast growth factor-related communication (e.g., via FGF19, FGFR4). This evidence concerns the gene FGF19 and neoplasm.